美迪西(688202) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 was CNY 280,304,304.26, a decrease of 9.83% compared to the same period last year[2] - Net profit attributable to shareholders was a loss of CNY 58,444,798.70, representing a decrease of 211.99% year-to-date[2] - Basic earnings per share for the year-to-date period was -CNY 0.96, a decrease of 203.23% compared to the same period last year[2] - The net profit for Q3 2024 was -128,675,088.23 RMB, a significant decline compared to the net profit of 114,900,869.11 RMB in Q3 2023[16] - The total profit for Q3 2024 was -161,891,596.84 RMB, compared to a profit of 119,347,196.63 RMB in the same period last year[16] - Operating profit for Q3 2024 was -160,506,352.85 RMB, a decrease from the operating profit of 119,659,284.83 RMB in Q3 2023[16] - Total operating revenue for the first three quarters of 2024 was ¥801,725,512.27, a decrease of 32.2% compared to ¥1,183,189,967.59 in the same period of 2023[14] - Total operating costs for the first three quarters of 2024 were ¥956,515,797.05, down from ¥1,065,803,867.08 in 2023, reflecting a reduction of 10.3%[14] Research and Development - R&D expenses totaled CNY 23,614,143.03 in Q3 2024, down 31.98% year-over-year[3] - The ratio of R&D expenses to revenue was 8.42%, a decrease of 2.75 percentage points compared to the previous year[3] - Research and development expenses for the first three quarters of 2024 amounted to ¥71,732,427.38, a decrease of 25.1% from ¥95,896,672.67 in the previous year[14] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,948,181,433.05, a decrease of 9.73% from the end of the previous year[3] - The company's total assets decreased to ¥2,948,181,433.05 in Q3 2024 from ¥3,265,847,480.54 in Q3 2023, representing a decline of 9.7%[13] - Total liabilities decreased to ¥596,326,012.22 in Q3 2024 from ¥755,068,116.91 in Q3 2023, a reduction of 21.1%[12] - The company's equity attributable to shareholders decreased to ¥2,351,855,420.83 in Q3 2024 from ¥2,510,779,363.63 in Q3 2023, a decrease of 6.3%[12] Cash Flow - Cash flow from operating activities was not applicable for the current period, with a year-to-date net cash flow of -CNY 68,749,348.95[2] - Cash flow from operating activities for the first three quarters of 2024 was -68,749,348.95 RMB, compared to -8,769,008.62 RMB in the same period of 2023[19] - Cash inflow from investment activities in Q3 2024 was 911,170,983.35 RMB, up from 426,713,927.73 RMB in Q3 2023[19] - Cash outflow from investment activities for Q3 2024 was 825,734,294.67 RMB, compared to 1,241,850,264.50 RMB in Q3 2023[19] - The net cash flow from financing activities for Q3 2024 was -128,771,566.61 RMB, a decrease from 1,158,070,037.64 RMB in Q3 2023[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,096[8] - The largest shareholder, Chen Jinzhan, holds 16,362,811 shares, representing 12.15% of total shares[9] Other Financial Metrics - Non-recurring gains and losses for the current period amounted to CNY 3,780,629.77, with a year-to-date total of CNY 13,152,699.47[5] - Cash and cash equivalents as of September 30, 2024, amount to ¥362,306,656.92, down from ¥471,870,185.67 at the end of 2023[10] - Accounts receivable increased to ¥644,574,473.01 from ¥591,002,959.52 year-over-year[10] - Inventory decreased to ¥109,102,073.10 from ¥165,518,376.11 year-over-year[10] - Total trading financial assets decreased to ¥292,579,561.49 from ¥518,231,957.07 year-over-year[10] - Other receivables increased significantly to ¥19,073,261.54 from ¥3,051,113.46 year-over-year[10] - Deferred tax assets increased significantly to ¥33,874,433.15 in Q3 2024 from ¥4,774,606.71 in Q3 2023, reflecting a growth of 610.5%[12] Operational Conditions - The company experienced a significant decline in revenue due to changes in the financing environment and intensified competition in the biopharmaceutical industry[6] - The company has not reported any significant changes in operational conditions during the reporting period[10] - The company has not issued any new guidance or outlook for future performance in this report[10]